Lazarev Alexander V's Form 4 filing
Pressure Biosciences Inc (PBIO) · filed Sep 16, 2021
- Accession no.
- 0001493152-21-022956
- Filed
- Sep 16, 2021
- Trade date
- Sep 14, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lazarev Alexander VCIK 0001394174 | Officer (VP of Research & Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series AA Convertible Preferred Stock converts into 1,000 shares of the Company's Common Stock at a conversion price of $2.50 per share.
Referenced by the price of 1 transaction in Table II.
- F2
Each Warrant gives the investor the right to purchase the number of shares of Common Stock equal to 100% of the number of shares of Common Stock issuable upon conversion of the total number of Series AA Convertible Preferred Stock units purchased, at an exercise price of $3.50 per share.
Referenced by the price of 1 transaction in Table II.